U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Tuesday.

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) fell sharply in today's pre-market trading as the company announced its collaboration and license agreement with Pfizer on giroctocogene fitelparvovec will terminate effective April 21, 2025.

Sangamo Therapeutics shares dipped 50% to $1.17 in the pre-market trading session.

Here are some other stocks moving lower in pre-market trading.

Now Read This:

• Top 3 Tech Stocks That May Fall Off A Cliff This Quarter